Liver transplantation and whipple surgery combined with chemoradiotherapy for treatment of hilar cholangiocarcinoma in patients with primary sclerosing cholangitis

2015 ◽  
Vol 21 (5) ◽  
pp. 696-699 ◽  
Author(s):  
Saman Nikeghbalian ◽  
Alireza Shamsaeefar ◽  
Ahad Eshraghian ◽  
Mohsen Reza Mansoorian ◽  
Kourosh Kazemi ◽  
...  
2021 ◽  
Vol 108 (Supplement_1) ◽  
Author(s):  
WA Cambridge ◽  
RV Guest

Abstract Introduction Despite improvements in survival for other tumour types, the prognosis of hilar cholangiocarcinoma (CC) continues to be extremely poor. Since publication of the Mayo protocol in 2000, an increasing number of case series around the world have reported excellent outcomes after neoadjuvant chemoradiation followed by liver transplantation (NCR-LT) in unresectable hilar CC. Method MEDLINE, EMBASE, Scopus and Web of Science databases were searched and data extracted from relevant studies. A proportional meta-analysis was conducted to pool 1, 3- and 5-year survival and disease recurrence rates following NCR-LT. Result Twenty studies comprising 428 patients were eligible for final analysis. The pooled 1, 3- and 5-year overall survival rates following LT without neoadjuvant therapy were 71.2% (95% CI 62.2 - 79.4), 48.0% (95% CI 35.0 - 60.9) and 31.6% (95% CI 23.1 - 40.7). These rates improved to 82.8% (95% CI 73.0 - 90.8), 65.5% (95% CI 48.7 - 80.5) and 65.1% (95% CI 55.1 - 74.5) following administration of a neoadjuvant chemoradiation protocol. The pooled recurrence rate was 51.7% (95% CI 33.8 - 69.4) in patients who did not undergo neoadjuvant treatment and 24.1% (95% CI 17.9 - 30.9) in those who did. Conclusion In unresectable hilar CC, NCR-LT confers long-term survival in selected patients able to complete neoadjuvant chemoradiation followed by transplantation. Patients with primary sclerosing cholangitis have the most favourable survival outcomes. A high disease recurrence rate is of concern when considering extending national graft allocation schemes. CC - Cholangiocarcinoma, NCR-LT - Neoadjuvant Chemoradiation & Liver Transplantation Take-home message In selected patients, the treatment of unresectable hilar cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation results in 5-year overall survival rates greater than 50%. Patients with hilar cholangiocarcinoma and concomitant primary sclerosing cholangitis have the most favourable outcomes post-transplantation.


2008 ◽  
Vol 14 (2) ◽  
pp. 245-251 ◽  
Author(s):  
Jacob Alexander ◽  
James D. Lord ◽  
Matthew M. Yeh ◽  
Carlos Cuevas ◽  
Ramasamy Bakthavatsalam ◽  
...  

2021 ◽  
Vol 14 (1) ◽  
pp. e235918
Author(s):  
Mary R Shen ◽  
Meredith Barrett ◽  
Seth Waits ◽  
Aaron M Williams

This case highlights a 37-year-old woman with primary sclerosing cholangitis awaiting liver transplantation who presented with torsion of a wandering spleen with associated gastric and pancreatic volvulus. The patient underwent emergent exploratory laparotomy with splenectomy. She had an uncomplicated postoperative course and recovered well.


2017 ◽  
Vol 23 (33) ◽  
pp. 6147-6154 ◽  
Author(s):  
Sonja Boyd ◽  
Marko Vannas ◽  
Kalle Jokelainen ◽  
Helena Isoniemi ◽  
Heikki Mäkisalo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document